Surabhi Dangi-Garimella, PhD

Articles

Study Finds HCV Infection Increases 10-Year Risk of Cardiovascular Disease

December 14, 2018

A combined analysis of data gathered from the Canadian Health Measures Survey and the US–National Health and Nutrition Examination Survey found a 2.5% to 3.5% increase in the 10-year risk of cardiovascular disease in patients with a hepatitis C virus (HCV) infection.

Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL

December 06, 2018

A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

HBV Reactivation a Serious Adverse Effect of DAAs in the Treatment of HCV

December 06, 2018

A kidney transplant patient treated with direct-acting antivirals (DAAs) for a chronic hepatitis C virus (HCV) infection showed reactivation of the hepatitis B virus (HBV), which proved fatal. The authors of the report recommend a call to action for including HBV testing as part of the patient’s work-up in transplant recipients who are on immunosuppressants, especially in the context of abnormal liver tests.

iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL

December 03, 2018

Ibrutinib combined with obinutuzumab had better progression-free survival (PFS) at 30 months than the standard chemoimmunotherapy regimen, chlorambucil plus obinutuzumab, regardless of high-risk genomic features in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who had never been treated.